SciVision Biotech EBIT

The latest EBIT for 1786.TW is $170M as of June 2026. That compares with $200M in the prior-year period — down 11.5% year over year. That is above the sector sector average of $-25M. Investors often review this figure alongside SciVision Biotech's historical trend and sector peers before judging valuation or financial health.

Over the past year, 1786.TW's EBIT moved from $200M to $170M — a 11.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in SciVision Biotech's operating scale or balance-sheet position.

Against its sector companies, 1786.TW currently prints $170M for EBIT, while the sector average sits near $-25M. That is roughly 786.7% above the sector mean. Large gaps often invite a closer look at SciVision Biotech's growth, margins, and balance sheet.

A EBIT figure of $170M for 1786.TW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-25M. Explore the charts below for those layers of context.

After noting 1786.TW's EBIT ($170M), review year-over-year change from $200M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.